The agency provides quality, development, manufacturing, and labeling recommendations.
On June 16, 2016, FDA published guidance on the Center for Drug Evaluation and Research’s (CDER) thinking in regards to the assessment of critical quality attributes in the development of chewable tablets. The guidance also addresses the submission of developmental, manufacturing, and labeling information in new drug applications (NDAs) and abbreviated NDAs (ANDA) for CDER approval. The guidance also applies to certain chemistry, manufacturing, and controls (CMC) supplements to NDAs and ANDAs.
Critical quality attributes that should be established during early development include hardness, dissolution, and disintegration of the chewable tablet. FDA also recommends the following when developing chewable tablets:
The guidance provides labeling information, a chewing difficulty index, and a simulated salivary fluid composition appendix.
Source: FDA
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.